Skip to main content
Nxera Pharma Co., Ltd. logo

Nxera Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 4565 ISIN · JP3431300007 LEI · 2138004M62BFNJMR2Z82 T Manufacturing
Open in API
Filings indexed 113 across all filing types
Latest filing 2025-12-12 Regulatory Filings
Country JP Japan
Listing T 4565

About Nxera Pharma Co., Ltd.

https://www.nxera.life/

Nxera Pharma Co., Ltd. (formerly Sosei Group Corp.) is a technology-driven biopharmaceutical company focused on the discovery and early development of novel medicines. The company utilizes its proprietary StaR® technology and world-leading expertise in G protein-coupled receptor (GPCR) structure-based drug design (SBDD) to create therapeutics for diseases with high unmet medical needs. By integrating advanced science and technology, Nxera Pharma develops its internal pipeline and collaborates with partners to accelerate the creation of life-changing treatments for patients worldwide. Its mission is to invest in science and technology to accelerate the development of these medicines.

Recent filings

Filing Released Lang Actions
訂正有価証券届出書（参照方式）
Regulatory Filings Classification · 95% confidence The document is a 'Correction of Securities Registration Statement' (訂正有価証券届出書) filed with the Kanto Local Finance Bureau. It details the issuance of Restricted Stock Units (RSU) as part of a compensation plan for directors and employees. In the context of Japanese financial filings, a 'Securities Registration Statement' (有価証券届出書) is a regulatory filing used for the issuance of new shares or securities. Since it does not fit into specific categories like 'Annual Report' or 'Earnings Release', and is a formal regulatory submission regarding capital structure/share issuance, it falls under the 'Regulatory Filings' category.
2025-12-12 Japanese
訂正有価証券届出書（参照方式）
Share Issue/Capital Change Classification · 95% confidence The document is a 'Correction of Securities Registration Statement' (訂正有価証券届出書) filed with the Kanto Local Finance Bureau. It details the issuance of new shares related to a Restricted Stock Unit (RSU) compensation plan for employees and executives. In the context of Japanese financial filings, a 'Securities Registration Statement' (有価証券届出書) and its corrections fall under the category of capital and financing updates, as they pertain to the issuance of equity securities. Given the provided categories, 'SHA' (Share Issue/Capital Change) is the most accurate classification for documents detailing the issuance of new shares and capital structure changes.
2025-12-05 Japanese
訂正有価証券届出書（参照方式）
Share Issue/Capital Change Classification · 95% confidence The document is a 'Correction of Securities Registration Statement' (訂正有価証券届出書) filed with the Kanto Local Finance Bureau. It details the issuance of new shares related to a Restricted Stock Unit (RSU) compensation plan. In the Japanese regulatory framework, a 'Securities Registration Statement' (有価証券届出書) is a formal regulatory filing used for public offerings or significant capital changes. Since this is a specific regulatory filing document rather than a general announcement, and it does not fit into categories like 10-K, IR, or RNS, it is classified as a Regulatory Filing.
2025-12-05 Japanese
訂正有価証券届出書（参照方式）
Regulatory Filings Classification · 95% confidence The document is a 'Correction of Securities Registration Statement' (訂正有価証券届出書) filed with the Kanto Local Finance Bureau. It details the issuance of new shares related to a Restricted Stock Unit (RSU) compensation plan. In the Japanese regulatory framework, a 'Securities Registration Statement' (有価証券届出書) is a formal filing required for public offerings or significant share issuances. Since this document does not fit into the specific categories of Annual Reports, Earnings Releases, or M&A, and is a formal regulatory filing regarding capital structure and share issuance, it is classified as a Regulatory Filing (RNS).
2025-08-08 Japanese
訂正有価証券届出書（参照方式）
Share Issue/Capital Change Classification · 95% confidence The document is a 'Correction of Securities Registration Statement' (訂正有価証券届出書) filed with the Kanto Local Finance Bureau by Nxera Pharma Co., Ltd. This document is a formal regulatory filing under the Financial Instruments and Exchange Act of Japan, specifically related to the issuance of new shares for a Restricted Stock Unit (RSU) compensation plan. Since it is a formal regulatory filing that does not fit into specific categories like earnings releases or annual reports, and is a primary regulatory document rather than an announcement of a report, it is classified as a Regulatory Filing.
2025-08-08 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically accompanying a Second Quarter Report (Interim Report). It confirms the accuracy of the financial statements for the period ending June 30, 2025. Since this is a formal regulatory filing confirming the contents of an interim report, it falls under the category of regulatory filings.
2025-08-08 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.